Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD.
Hematol Oncol
; 42(5): e3299, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-39132926
ABSTRACT
Patients with advanced-stage Hodgkin lymphoma treated with ABVD who have a positive interim FDG-PET (iPET) have a poor prognosis. Escalation to BEACOPP has been shown to improve progression-free survival (PFS). However, randomized trials are lacking to determine the best strategy for intensification. We report on A-AVD escalation treatment outcomes for 15 iPET-positive patients post-ABVD. Overall response and complete response rates were 80% and 60%, respectively. Four patients underwent salvage therapy followed by autologous stem cell transplantation. At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vinblastine
/
Bleomycin
/
Hodgkin Disease
/
Antineoplastic Combined Chemotherapy Protocols
/
Doxorubicin
/
Dacarbazine
/
Positron-Emission Tomography
/
Brentuximab Vedotin
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Hematol Oncol
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: